28 completed, 19 terminated, 3 withdrawn, 2 unknown. 52 Phase 2, 16 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 52 | Completed 28, Terminated 19, Withdrawn 3, Unknown 2 |
| Phase 1 | 16 | Completed 10, Terminated 3, Unknown 2, Withdrawn 1 |
Follow LBH589: new trials by email Literature Review of LBH589 trials Research Report on LBH589
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Carfilzomib, Chemosensitivity Assay, Dexamethasone - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Terminated | University of Washington | 9 | 2018-02-08 | 2022-05-09 |
| Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat Panobinostat, Carfilzomib, Lenalidomide - Multiple Myeloma | Phase 1 / Phase 2 | Withdrawn | H. Lee Moffitt Cancer Center and Research Institute | 2017-06-01 | 2017-04-25 | |
| Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma Dexamethasone, Panobinostat, Liposomal vincristine - Acute Lymphoblastic Leukemia, Lymphoma, Non-Hodgkin's | Phase 2 | Terminated | St. Jude Children's Research Hospital | 3 | 2016-11-23 | 2019-04-03 |
| Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT) Panobinostat - Multiple Myeloma | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 30 | 2016-06-10 | 2022-11-01 |
| Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy Panobinostat, Pegylated Interferon-alpha2a - HIV Infection | Phase 1 / Phase 2 | Completed | Massachusetts General Hospital | 17 | 2016-05-01 | 2024-02-28 |
| Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma Panobinostat Capsules, Bortezomib Injection, Dexamethasone tablets - Multiple Myeloma | Phase 2 | Completed | pharmaand GmbH | 248 | 2016-04-27 | 2024-07-12 |
| Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Gemcitabine Hydrochloride - Plasma Cell Leukemia, Plasmacytoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 83 | 2015-09-14 | 2025-03-18 |
| Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial) Panobinostat, Ruxolitinib - Myelofibrosis | Phase 1 / Phase 2 | Completed | John Mascarenhas | 15 | 2013-01-01 | 2023-10-31 |
| Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART Panobinostat - HIV Infection | Phase 1 / Phase 2 | Completed | University of Aarhus | 15 | 2012-09-01 | 2014-02-25 |
| Panobinostat Biological Correlates Study panobinostat - Nodal Lymphoma, Lymphoma With Cutaneous Involvement | Phase 2 | Completed | Peter MacCallum Cancer Centre, Australia | 30 | 2012-07-16 | 2022-05-06 |
| Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM) Panobinostat, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 2 | Completed | Ajai Chari | 32 | 2012-07-01 | 2018-04-09 |
| Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) RAD001, LBH589, Doublet (RAD001 and LBH589) - Diffuse Large B-cell Lymphoma | Phase 2 | Terminated | Anne Beaven, MD | 50 | 2012-02-01 | 2016-11-25 |
| A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma panobinostat, lenalidomide - Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 24 | 2011-10-13 | 2017-11-14 |
| Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma Panobinostat with Rituximab - Diffuse Large B Cell Lymphoma | Phase 2 | Terminated | Massachusetts General Hospital | 18 | 2011-06-01 | 2017-05-09 |
| Oral Panobinostat Adult Patients DLBCL Relapsed/Refractory Stem Cell Transfusion (ASCT) or Not Eligible for ASCT Panobinostat - Diffuse Large B-cell Lymphoma | Phase 2 | Completed | Fondazione Italiana Linfomi - ETS | 35 | 2011-02-01 | 2019-11-22 |
| Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma panobinostat, laboratory biomarker analysis, western blotting - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Completed | Mayo Clinic | 41 | 2011-01-17 | 2022-05-24 |
| Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Panobinostat - Myelodysplastic Syndrome, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Johann Wolfgang Goethe University Hospital | 62 | 2011-01-01 | 2018-03-20 |
| A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL) LBH589, Rituximab - Diffuse Large B Cell Lymphoma | Phase 2 | Completed | Sarit Assouline | 42 | 2010-11-01 | 2023-03-24 |
| Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy Bortezomib, Panobinostat - Pancreatic Cancer | Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 7 | 2010-09-01 | 2017-12-28 |
| Re-expression of ER in Triple Negative Breast Cancers Decitabine, LBH589, Tamoxifen - Breast Cancer, Breast Tumors | Phase 1 / Phase 2 | Terminated | Emory University | 5 | 2010-07-01 | 2015-01-26 |
Showing 20 of 52. Sign in to see all of them.
Multiple Myeloma (12) · Recurrence (7) · Lymphoma, Large B-Cell, Diffuse (6) · Myelodysplastic Syndromes (5) · Hodgkin Disease (4) · Lymphoma, T-Cell, Cutaneous (4) · Mycosis Fungoides (4) · Sezary Syndrome (4) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma (3) · Lymphoma, Mantle-Cell (3) · Lymphoma, Non-Hodgkin (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Primary Myelofibrosis (3) · Waldenstrom Macroglobulinemia (3)
Novartis Pharmaceuticals (12) · H. Lee Moffitt Cancer Center and Research Institute (3) · M.D. Anderson Cancer Center (3) · SCRI Development Innovations, LLC (3) · Massachusetts General Hospital (2) · Mayo Clinic (2) · Ajai Chari (1) · Anne Beaven, MD (1) · Dana-Farber Cancer Institute (1) · Duke University (1) · Emory University (1) · Fondazione Italiana Linfomi - ETS (1) · Johann Wolfgang Goethe University Hospital (1) · John Mascarenhas (1) · Masonic Cancer Center, University of Minnesota (1)
United States (43) · Germany (9) · Australia (5) · Belgium (4) · Italy (4) · Canada (3) · France (3) · Spain (3) · Brazil (2) · Hungary (2) · Argentina (1) · Czechia (1) · Denmark (1) · Finland (1) · Greece (1)
Ajai Chari, MD (1) · Alessandro Levis, MD (1) · Andrew Cowan (1) · Anna Ferrari, MD (1) · Anne Traynor, M.D. (1) · Anne W. Beaven, MD (1) · Arkadiusz Dudek, MD (1) · Atae Utsunomiya (1) · Celeste Bello, M.D. (1) · Daniel R Couriel, M.D. (1) · Daniel R Kuritzkes, MD (1) · David A Reardon, MD (1) · Geoffrey Uy, M.D. (1) · Gesine Bug, MD (1)
PMID 25939707, PMID 21984064, PMID 22072492, PMID 22981498, PMID 23287861, PMID 23701016, PMID 23822537, PMID 23950178, PMID 24135804, PMID 25062770, PMID 25572329, PMID 26423811, PMID 26696749, PMID 27166360, PMID 27740633, PMID 28622959, PMID 29296798, PMID 30830886, PMID 31654285, PMID 31778911, PMID 33301738, PMID 34482353, PMID 39863139
2005 (1), 2008 (1), 2009 (1), 2015 (1), P30CA015083 (1), P30CA015704 (1)